Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Gross Margin (2016 - 2025)

Cumberland Pharmaceuticals' Gross Margin history spans 16 years, with the latest figure at 7.26% for Q4 2025.

  • For Q4 2025, Gross Margin rose 1239.0% year-over-year to 7.26%; the TTM value through Dec 2025 reached 57.1%, up 1037.0%, while the annual FY2025 figure was 57.1%, 206.0% up from the prior year.
  • Gross Margin for Q4 2025 was 7.26% at Cumberland Pharmaceuticals, down from 88.08% in the prior quarter.
  • Across five years, Gross Margin topped out at 145.63% in Q4 2022 and bottomed at 19.65% in Q4 2024.
  • The 5-year median for Gross Margin is 63.87% (2025), against an average of 59.25%.
  • The largest annual shift saw Gross Margin crashed -7941bps in 2021 before it soared 16017bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 14.54% in 2021, then surged by 1102bps to 145.63% in 2022, then crashed by -63bps to 53.63% in 2023, then tumbled by -137bps to 19.65% in 2024, then surged by 63bps to 7.26% in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Gross Margin are 7.26% (Q4 2025), 88.08% (Q3 2025), and 107.33% (Q2 2025).